In the medical journal The BMJ, the World Health Organization advocated the arrival of two new treatments: baricitinib and sotrovimab.
Intended for specific patients, the WHO has validated the sotrovimab, treatment with synthetic antibodies and the baricitinib, usually used against rheumatoid arthritis.
Mild Covid and or severe or critical Covid
Regarding sotrovimab, it is recommended for patients with mild Covid whose high risk of hospitalization is high; As for baricitinib, it will be offered to patients with severe or critical Covid, it will be associated “in combination with corticosteroids”. In the end, the World Health Organization (WHO) recently authorized five new treatments against Covid-19.
Five new treatments for Covid-19
As for monoclonal antibodies, other authorizations have been issued such as Ronapreve which is marketed in France but which remains offered to patients at risk of severe Covid. Very recently, the HAS (Haute Autorité de santé) validated a second cocktail of monoclonal antibodies developed by AstraZeneca with Evusheld. For the infectious disease specialist and director of the National Agency for AIDS Research (ANRS), Yazdan Yazdanpanah, to “overcome this pandemic, you have to use a lot of tools and monoclonal antibodies are part of it”, indicates the doctor.
Thursday: 24,000 patients with Covid-19
Yesterday, just over 24,000 patients with Covid-19 were hospitalized in France. About 4,000 were in critical care. 966,000 PCR and antigen tests were carried out in France between January 3 and 9, 2022. For their part, our Spanish neighbors gave the green light to a 4th dose of anti-Covid vaccine for certain very vulnerable people such as the immunocompromised.
–
